Animal Models and Experimental Medicine · 2022 · 12 citations · 31 references
MedicineDermatologyPathobiologyImmunopathologyImmunoregulationInflammationAnti-inflammatory PharmacologyAtopic DermatitisImmunopathology Of SkinInflammatory DermatosesInflammatory Skin DiseasesInflammatory Skin DisordersAtopic Dermatitis ImmunopathologyAtopic Dermatitis PathologyAtopic Dermatitis TreatmentChronic Inflammatory Disease ModelsCytokine Production By Mast CellsCytokine-mediated Skin InflammationImmunomodulatory CytokinesInflammatory Skin Responses
BACKGROUND: Amarogentin (AMA) is a secoiridoid glycoside extracted from Swertia and Gentiana roots and exhibits many biological effects such as antioxidative, anti-inflammatory, and antitumor activities. Atopic dermatitis (AD) is a chronic inflammatory skin disease caused by disorders in the regulation of multiple inflammatory cytokines. No effective cure has been found for AD now. METHODS: We constructed the HaCat and splenocyte model and tested the inhibitory effect of AMA on IL-4, IL-6, and IL-13 secretions using enzyme-linked immunosorbent assay (ELISA). The AD mouse model was constructed and treated with AMA, the severity of skin lesions was observed, epidermal tissue was collected, and epidermal thickness and mast cell infiltration were observed using hematoxylin and eosin and toluidine blue staining, respectively. The expression of kallikrein-related peptidase 7 (KLK7) and filaggrin (FLG) was detected using immunostaining and Western blot analysis. The mRNA expression of KLK7 and FLG was detected using quantitative polymerase chain reaction (qPCR). Blood immunoglobulin E (IgE) secretion was detected. RESULTS: AMA inhibited IL-6 secreted by tumor necrosis factor (TNF)-α-induced HaCaT cells and reduced IL-4 and IL-13 secreted by phytohemagglutinin (PHA)-induced primary cells in the mice spleen. It was found that the treatment of AMA with 2,4-dinitrochlorobenzene-induced AD-like mice could promote the recovery of dermatitis, reduce the score of dermatitis severity and the scratching frequency, treat the skin lesions, reduce the epidermal thickness, decrease the infiltration of mast cells, reduce the IgE level in serum, decrease the expression levels of AD-related cytokines, increase protein and mRNA expression of FLG, and reduce the protein and mRNA expression of KLK7 in the skin tissues of AD-like mice. CONCLUSION: In conclusion, AMA inhibits inflammatory response at the cellular level, and AMA reduces the validation response of specific dermatitis mice, relieves pruritus, and repairs the damaged skin barrier.
31
Cytokine modulation of atopic dermatitis filaggrin skin expression
Michael Howell, Byung Eui Kim, Peisong Gao et al. · Journal of Allergy and Clinical Immunology · 2007 · 1.1K citations · Full text
Medicine, Dermatology, Immunology +14
Guidelines of care for atopic dermatitis
Jon M. Hanifin, Kevin D. Cooper, Vincent Ho et al. · Journal of the American Academy of Dermatology · 2004 · 389 citations
Leigh Nattkemper, Hong Liang Tey, Rodrigo Valdés‐Rodríguez et al. · Journal of Investigative Dermatology · 2018 · 308 citations · Full text
Life Sciences, Dermatology, Genetics +15